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Summary  findings
Bishai, Lin, and Kiyonga delineate two different  Under an "equity" model - allocating vaccines to
algorithms for the purchase of AIDS vaccines, to show  everyone in the world at high risk as if they had the
how differences in policy objectives can greatly affect  financial resources of Western Europeans - vaccine
projections of the number of courses of vaccine that will  would be offered to 4.7 billion people. For a Western
be needed.  European man, reducing the risk of HIV/AIDS would be
They consider a hypothetical vaccine costing S10 to  a $789 concern; in Africa, the cornparable risk would be
produce, and offering 60 percent, 75 percent, and 90  a $48,577  crisis.
percent reductions in the risk of HIV for 10 years. For  The authors conclude that financing AIDS vaccines
each of the world's  10 major geographic divisions, they  solely on the fixed budget of a ministry of health rmeans
use published estimates of the risk of AIDS, the value of  large vulnerable populations wouldn't  receive the
medical costs averted, and the value of potential  vaccine. Allocating the vaccine based on society's ability
productivity losses.  to pay would still exclude many poor infants who would
Under the "health sector" algorithm - in which  probably be immunized if they were born in more
purchases are made to minimize the impact of AIDS/HIV  developed regions.
on government health spending - 766 million courses  Policymakers concerned about equity in health care
of vaccine would be purchased. Under the "societal"  must redouble efforts to making the financing of
algorithm - in which purchases are made to minimize  development and distribution of AIDS vaccines a global,
the impact of AIDS!HIV on health spending and GDP - not a regional, concern.
more than 3.7 billion courses of vaccine w-ould  be
purchased.
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2introduction
In this paper we attempt to answer the question, "'If an AIDS vaccine arrived in the world
on 1 January 2000, what are the ramifications  of two different decision algorithms,  in terms of who
would get the vaccine  and how  many  would be needed?" Anticipating the answer to this question will
aid policy  makers as they prepare for the efficient  and equ.table use of an AIDS vaccine.
An effective  AIDS vaccine does not yet exist. Foxecasting  what will happen when a vaccine
is developed is difficdlt. Unforeseen changes in the fundamnental  determinants of demand for a
vaccine  will occur betiween  now and the time when a vaccine  is released. These determinants not
only include the epidemiology  of AIDS/HIV, the world's,  demographic  makeup, and the economic
resources  available  for health, but also the properties of th. vaccines  themselves. Developments in
vaccine production capacity  and technology could change the determinants of supply. Because all of
these unknown factors are interrelated, an attempt to simultaneously  offer 10-year  forecasts would
lack credibili.ty.  Thus, rather than project what demand will  be in the year 2010, we profile who the
most likely  vaccine  tecipients would be in the year 2000 ac:cording  to 2 different algorithms. We
enumerate likely  vaccine  recipients under each algorithm as a function of possible vaccine  price
regimes.
METHODS
Health  Sector  versus  Societal  Perspective
To select algorithms for AIDS vaccine allocation that are relevant to what might actually
occur, we employ  what is known from empirical  studies of national decisions to purchase other
vaccines. It:  has been shown from studies  of the uptake cf Hepatitis B and Hemophilus Influenza B
vaccines that a courntry's  adoption of a vaccine  depends on the cost of the vaccine, the incidence of
the disease,  the GDP/capita, and the cost of the consequences  of the disease (Brooks et al. 1999;
Miller  and Flanders 1999).  There are two possible perspectives on the costs of an illness: 1) The
health  sectorperspective  in which the cost of an illness is the let present value of the sum of the costs of
3the medical care required by the victims;  and 2) The  socetalperirpective  in which the cost of an illness is
not only the medical  costs but the lost productivity of workers and families affected by the disease
(Gold et al. 1996). Neither of these perspectives ordinarily  includes the immense intangible costs of
pain, suffering,  and bereavement that are borne by individuals. The decision that countries will
eventually  have to make regarding the purchase of the AIDS vaccine could be motivated by either of
these two perspectives on the cost of disease. The model that currently appears to be most prevalent
for vaccine purchase decisions by health ministries is the health sector perspective. The government
health ministry is allocated  a fixed  budget and asked to allocate  purchases for all items (including
vaccines)  to maximize a population's health under that budget.
Health ministries may consider other objectives  besides maximizing  population health.
Phoolcharoen et al (1999)  consider a case where the health rministry  saw its primary role as allocating
vaccine  to minimize  the contagion externality  regardless  of the impact of AIDS on its own operating
budget. Although such policies  may be adopted in the future and may prove to be valid disease
control strategies, there are few historical  occurrences of vaccine policies selectively  targeting those
most likely  to be contagious among a vast pool of susceptibles. Our algorithms whose principal
objective is lirniting  the budgetary impact of AIDS will account for the budgetary ramifications of
special  populations with a high propensity to spread disease.  This does lead to different priorities
from policies  which make the minimization of secondary  spread the principal objective.
AIDS Vaccine  Characteristics
We base our assumptions about the characteristics  of an AIDS vaccine on known properties
of current vaccines. Vaccination efficacy  will be sequentially  modeled at 60%, 75%, and 90% efficacy
with a duration of exactly 10 years.  For example a recipient of a vaccine  with 75% efficacy
experiences  an immediate 75% reduction in the risk of contracting  AIDS over the next decade.
Lacking  any basis to predict how risk behavior may change as a result of vaccination  we assume it
will be constant. With vaccines of low efficacy,  vaccine  induced increases in risky behavior could
4have serious  repercussions for policy (Anderson and Garnet: 1996). Were we to apply our
algorithms to vaccines  of lower efficacy  they would certainly  require adaptation to account for
behavioral effects of vaccine. There is an urgent need for erapirical  data on the behavioral responses
of participants in vaccine trials.
Eventual responders cannot be distinguished  from non-responders ex ante. We assume
adverse  effects of the vaccine  are temporary and self-limited.  We assume transportation and
administration  costs are no different for the AIDS vaccine than for current vaccines. We assume
that the vaccine's protection will last at least 10 years. We do not consider here any applications  of
the vaccine  to reduce viral shedding or viral load in those already  infected. We assume that
administering  the vaccine  to a susceptible  pregnant woman protects the woman and is safe for the
fetus. Infants born to pregnant vaccine recipients  are susceptible  until they themselves are
vaccinated.
We profile potential vaccine  recipients  by first divicing the world's population geographically
into the major geographical  regions established  by the UN. We arbitrarily  classify  as "less developed
countries"  (LDCs):  North Africa/Middle East, sub-Saharan Africa,  South/South-East Asia, Eastern
Europe/Central Asia, East Asia/Pacific, Caribbean,  and Ladin  America. We arbitrarily  classify  as
"more developed countries" (MIDCs):  Western Europe, North America,  and Australia/New Zealand.
There are obiious grounds for many specific  exceptions.  The one exception we did allow was to
considerJapan, Korea, and China separately  from the East Asian  Region to narrow the otherwise
wide variation in HIV economics and risk in this region.
Within each region we disaggregate  the general population into 4 groups on the basis of age
and sex. In  'able 1 we propose a possible further breakdown of the groups most likely  to be
considered  individually  for vaccine receipt due to their high risk. Table 1 indicates there is little
comprehensive  data upon which to base population estimaies for high risk groups such as
commercial  sex workers (CSWs),  injection drug users (IDU  s), and men who have sex  with men
(MSM)¢  in each region of the world. The likelihood  that these populations would be targeted by
5public health campaigns  could influence the allocation of an AIDS vaccine. Here we analyze  models
that incorporate estimates of the numbers of comrnercial  sex workers, IDUs, and MSM, but we note
that  the small size of these groups relative  to the general population make estimates of the total need
for vaccine relatively  robust to their inclusion or exclusion  in the model.  In this paper we present
the details  relevant to the general populations and selected high-risk  populations.
Decision Rule Algorithm
We developed the following  simple algorithm  to profile the regional subgroups as vaccine
recipients  or non-recipients based on the "marginal benefit" (MB) of allocating  AIDS vaccines  to
that group. Group j is a "vaccine recipient" if MB,>P; otherwise it is a non-vaccine recipient.
[Rule 1]
Where P is total price of a complete course of vaccine (including  administration  costs) and MBi  is rnarginal
benefit of extending vaccination  to include group j. MBj  is given as follows:
MB, (Health Sector Perspective) =E  X  Ilo  x (1+Nj ) x [PV(HC,)]  -VC 1 [Equation 1]
Where:
E  =  vaccine efficacy  from 0-100%,  assumed=75% for exactly  10 years in baseline analysis.
Ijlo  decadal  incidence of HIV expressed as the discounted likelihood  that the average person in
group j will seroconvert in the next 10 years.
Nj  =  the number of secondary  cases that infected individuals  in this group cause over 10 years
PV  =  denotes present value computed at a 3% discount rate
HCj =  health care costs between the onset of HIV/AIDS and death
VCj =  vaccine  administration cost
We call Equation 1 the "health sector perspective" because it might reflect the perspective of a
minister of health searching for investments which miniimize  the drain that a given disease poses to
an arbitrarily  fixed health sector budget. We also compute MB 1j from a societal  perspective alternative
that includes  lost productivity.
MBj (Societal Perspective) =E x ljlo  x (1+Ni ) x [PV(HCi + Wj))] -VCi  [Equation 2)
Where: Wj  =  lost lifetime  wage after the onset of total disability  from AIDS.
6Comrrputing  MB 1 according to equation 2 for each subgroup in each region produces what we
call the "societal perspective", because the presence of lost productivity  in the estimates makes MB 1
reflect the perspective of a typical  minister of finance searching for investments that would maximize
the country's GDP.  'Equations  1 and 2 conform loosely  tc perspectives that might be taken by
hypothetical social  planners deciding to allocate  AIDS vaccine to subgroups of a region.  Since a
planner pursuing either of these simplified  objectives  would end up explicitly  rationing vaccine to
individuals  based on their economic status, neither algorithm  is ethically  appropriate if an equitable
distribution is of value. To indicate the degree of inequity  in vaccine distribution inherent in these
two simple 2lgorithrrms  we recalculate  MBj  throughout the world  based on each group's AIDS/HIV
incidence,  but with Western European values for medical spending  and lost productivity. We call
this exercise the "equit perrpective'.
To implement the algorithm  we gathered second&ry  data for each regional subgroup on HIV
incidence(Bernard  et:  al. 1998;  UNAIDS and WHO 1998a),  medical  care costs (Mann, Tarantola and
Netter 1992), and GDP/Capita  (World Bank 1998).  Sensitivity  analysis  of models incorporating high-
risk groups demonstrated that estimates of the number of secondary  cases spread by CSWs and
IDUs was unnecessary-according  to the algorithm their own high risk rendered them vaccine
recipients  whether cr not they infected any secondary  casqs. We assume that for the general
population that the number of secondary  cases caused  is negligible  and make the approximation that
Nj =0
After using the algorithms to profile each subgroup as a "recipient" or "non-recipient", as a
function of the vaccine price, we tabulated the cumulative  population of recipients across all
subgroups, based on demographic data for cohorts define  d by age and sex. (United Nations 1997)
Medical Care Costs
We assume that in the developed world, a patient would begin to incur medical costs on
average  about 2 years after seroconverting and incur them for 10 years before succumbing to
7disease(Curran  et al. 1988). In the developed countries significant  medical costs are incurred through
the use of highly active antiretroviral therapy (HAARI) for asymptomatic  seropositive patients. The
two-year  duration reflects delays  in seroconversion  and delays  in diagnosis  of seroconverions. Prior
to the development of HAART and improvements in opportunistic disease  prophylaxis,  the time
between seroconversion and death was thought to be 10 years (Bartlett 1998).  Responders to
HAART may have dramatically  prolonged survival,  but it is too soon to tell. Indeed the very best
answer to the question, "How long between seroconversion  and death in the developed world in
1999?"  is "Nobody knows." It is likely  that HAART will increase the total medical  costs per case of
AIDS, so we treat this possibility  in our sensitivity  analysis.
We assume that in developing  countries, an adult patient would begin to incur medical costs
5 years after seroconverting and incur them for an average of 2 years (Morgan  et al. 1997). The
natural history of HIV/AIDS in children regarding mean time to AIDS and mean time to death does
not appear to deviate markedly  from adults(Barnhart  et al. 1996). Our model neglects possible
regional differences  in care seeking behavior  and opportunistic infections that might lead adult
groups to spend more on treatments than children. Little  is known about these differentials. Thus
medical  costs are assumed to be the same for all ages and sexes.  We discount the medical costs and
lost wage costs by 3%. Estimates of the actual medical care costs of AIDS in each region are derived
as shown in the appendix.
Productivity  Costs
We assume that adults who seroconvert would withdraw from the labor force after six years
in developed countries, and after four years in developing countries. In withdrawing from the labor
force these patients would cease to add valuable  goods and services to the economy. We assume that
in every  country for adults age 15-49 that the average age for the onset of AIDS is 30 and that
retirement age is 65. AIDS thus yields 35 years of productivity  loss. We compute the present value
of this loss using a discount rate of 3%. As a measure of the value of these lost goods and services,
8we use the regional GDP/Capita and apply it to both men and women. GDP/capita is a coarse
measure of economic  well being; however,  there are few alternative  measures. The global
perspective of this paper makes it infeasible  to account for the complex adaptation any individual
economy may make to the loss of many productive workers (Over et al. 192). Furthermore, the
morbidity and mortality of AIDS impose an intangible  burden of pain and suffering  that the GDP
cannot possibly  reflect.
Vaccine  Administration  Costs
A full consideration of the delivery  costs would include the costs of marketing the vaccine to
individual  target groups (Cutts,  Orenstein and Bernier 1992;  Kim-Farley  and EPI Team 1992).
However, we sus  pec: that in many parts of the world, the word about the vaccine  will spread quickly-
-along  with inisinformation  about its safety and efficacy. Mduch  of the marketing  costs will depend
on what sorts of local rumors are spread about the vaccine and how deeply they are entrenched
(Nichter 1995).  Lacking a basis to estimate marketing  costs we focus on administration  costs.  In
developed cDuntries,  we take as an estimate the physician fee ($4.21)  for therapeutic injection in the
U.S. (CPT 90782) (Flealth Care Financing  Administration 1998).  In less developed countries, the
administration  cost of adding an additional  vaccine to the EPI program has been estimated at $0.50
(Hall  et al. 1993).
Results
Table 2 presents present value estimates of the lifetime cost of a single case of AIDS in each
region of the world for children, teens, adult men, and addlt women. The costs are presented for
both the societal and the health sector perspective. These estimated medical costs range from a low
of $38 per case of  E[IV/AIDS  in sub-Saharan  Africa to a high of nearly  $300,000  per case in North
America. I'he large variation in costs is due to both variation in the availability  of costly treatments
and variation in survival.
9The societal costs are lower for infants than for children because the eventual lost lifetime
productivity  is discounted by more years. The societal  costs are higher for children than adults
because more years of productivity  are lost on average for a child or teenager who is infected.
The  Benefit  of AIDS Vaccines
Given our estimates of HIV seroconversion  risk, vaccine efficacy,  and the economnic  loss, we
can compute MB for each target group using Equation 1 for the health sector perspective, and
Equation 2 for the societal  perspective. These results are displayed  in Tables 3 and 4.
Reviewing  the health sector perspective,  the groups with negative benefits (Table 3) are generally  at a
very low immediate risk of HIV, and primarily  are infants of low risk mothers or those people
residing in countries where the lack of treatments for HIV/AIDS makes the medical cost of the
disease  artificially  low. Comparing  the actual estimates of vaccination benefits to the benefits
developing  countries would gain if their medical spending  were that of Western Europe indicates that
as more medical treatments begin to be provided to HIV/AIDS patients the value of an AIDS
vaccine  in developing countries will only  increase.
Table 4 shows the net present benefits of vaccination  from the societal perspective. The
table shows that if the goal is to maximriize  the GDP, there are few population groups anywhere  in
the world with an HIV risk so low that vaccine administration  costs exceed the benefits. A person in a
high-risk  region like sub-Saharan Africa faces a greater than 10% chance of annihilation from
HIV/AIDS. Thus, it is not surprising that the benefit of removing this threat is a large fraction of the
remaining  lifetime  incomes shown in Table 2. The values in Tables 3 and 4 should be interpreted as
the returns per individual  from an investment in AIDS vaccine, not as a prediction of what
individuals  would actually  spend to obtain these returns. Poor populations have difficulty  financing
such large  investments despite their manifest importance.
The parenthesized values in Tables 3 and 4 indicate  the benefit that a Western European
would derive from the AIDS vaccine  if they faced the same risk as corresponding groups in othet
10areas of the world. This exercise offers a lens with which tc view the economics  of the AIDS
epidemic from a standardized  perspective.  The relatively low risk of a Western  European  man makes
reducing  that HIN/AIDS  risk a $789 nuisance,  but if that  same man were to confront  the
HIV/AIDS  risk of an African then this threat would be a $48,577 crisis.
Vaccine Demand  Curves
Each  different  algorithms  is designed to label the various  subpopulations  of the world  as
"vaccine recipients"  or "non-recipients"  as the price of vaccine varies from  $200 to $1.00 per course.
The graphs enumerate  the number  of vaccine recio,ients as a function  of the price of vaccine.
Figure  1 does  this according  to the health  sector decision  algorithm.  Figure 2 shows  the "demand
curve" that would be generated  from the  societal perspective  algorithm.  We use the  term  "demand
curve"  to suggest isomorphism  to the typical price vs. quaintity graphs from  economics.  We do not
mean to suggest that  the quantity demanded  on the horizontal  axis will result  from  the aggregate
decisions of individual households  in a private market.  However,  country  level decision-makers  are
very likely to make purchase  decisions as a function  of price.  Country level heterogeneity  in HIV risk
and national  resources will lead countries  of low financial resources and/or  low risk to defer vaccine
adoption  until the ptice  becomes  quite low. These  curves  ignore the constraints  that  poor
populations  will face in obtaining  sufficient financing to purchase  a quantity  of vaccine that  achieves
an optimal  allocation according  to the algorithm.  Estimates  of these financing  shortfalls  are
discussed below.
The callout boxes in Figures  1 and 2 identify some  of the main  sub-populations  that make
the transition  from  non-recipients  to recipients as the price goes down.  The callout boxes  are far
from  comprehensive  as there are over  91 separate subpopulations  being  tracked  (13 regions  x  7 risk
groups).  The general pattern  depicted  by the callout boxes is that at high prices the vaccine
recipients  have very high risk or very high medical and productivity  costs of AIDS.  As the price
drops  below  $25,  (Health  Sector Algorithm)  and below  $50 (Societal Algorithm)  very large
11populations from less developed countries convert to vaccine recipients and account for highly
elastic  price response at the lower price ranges.
Sensitivity Tests
To test the robustness of our model to our estimates of incidence we re-estimated the
demand curves with the assumption that incidence  was 25% lower and 25% higher for each
population. These alternative demand curves are displayed  as dotted lines in the figures. Testing
sensitivity  to the cost assumptions by altering  assumed medical  and productivity costs by ± 25%
generates  identical  results to those plotted as dotted lines in Figures 1 and 2, due to the structure of
the equations.
Assumptions about vaccine efficacy  also affect the number of vaccines distributed by the
algorithm. The dotted lines in Figures 3 and 4 plot out how much more or less vaccine  is distributed
if the vaccine lowers risk by 90% or 60%.
Discussion
Limitations
On a population basis,  it is reasonable to conduct policy  analysis using the notion of
population risk. Caution is warranted however, however, because the risk of HIV/AIDS  is not the
same for every individual  in a group. The possibility  of safer lifestyles  makes a vaccine an optional
but not unique way to prevent HIV/AIDS.  If one were to survey individuals  on how much they
would pay for an AIDS vaccine,  responses would likely  diverge from our values based on differences
between an individual's  own perceived HIV risk and the population risk measures our model would
impute to him.  Some individuals  who are able to choose an absolutely  risk free lifestyle  may choose
to never obtain an AIDS vaccine. For now, our model makes the arbitrary  assumption that all
individuals  above age 49 are categorically  able to eliminate  their HIV risk through safe lifestyles.  This
achieves  simplicity  at the expense of disregarding  the evidence that risk free lifestyles  exist for
12individuals  in younger cohorts and that HIV continues to be transmittecd  between individuals  well
beyond age 49.
Policy  Analysis  for  a $10  Vaccine
Until an AIDS vaccine  is discovered, the marginal  cost of producing it is unknown. The
claim by industry (DIupuy  and Freidel 1990)  that there are increasing returns to scale  in the
production of vaccine  suggests that in the first few years o:f  vaccine  production, the cost could be
significantly  higher than for subsequent generations of vaccine users. Unless firms are given
incentives  to rapidly  extend capacity,  it could be an additional  decade er  thefirst  vzacne  before one
could expect an AIDS vaccine  whose marginal production cost for a course is less than $1.00.
Perhaps after this decade, additional factories  will  have been built throughout the world to reap
returns to scale.
Suppose the marginal  cost just to produce and deliver  a single course of the first generation
of vaccine  is $10.00. The health sector allocation strategy  suggests that 766 million  people would
obtain benefits in excess of $10.00  and hence would  wish to buy the vaccine. The model predicts
that of these roughly 235 miDlion  are estimated to be in LDCs.  In contrast, the societal allocation
strategy sug,ests thalt  3.7 billion  persons (3.3 bilion in LDCs) would obtain benefits in excess of
$10.00.  The equity model  predicts that if everybody  in the world had the resources of Western
Europe, virtualy everybody  in the world under the age of 49 (4.7 bilion out of 4.8 billion) would
bear sufficient  HIV risk to justify  a $10.00  investment in AIDS vaccine.
Which  Vaccine  Allocation  Curve?
Health ministries  in regions like  Africa would stil be reluctant to purchase vaccine at a $10
price because $10.00 per person would exhaust al of the average annual health ministry budget. Our
model predicts that it would require a $9.00 purchase subsidy  to make the most optimal vaccine
purchase affordable for health ministries  in sub-Saharan  Africa. With a $9.00  subsidy, a typical sub-
13Saharan health ministry could expect to recoup its own $1.00 outlay  in the form of reduced medical
expenditure for HIV/AIDS.
In contrast to health ministries,  our model predicts that treasury departments in every region
of the world ought to be willing  to spend $10.00  per citizen on AIDS vaccination for large portions
of the teenage and adult populations. Such investment decisions would pay their way through
enhanced survival  of working populations. Indeed, there is a growing recognition that confronting
AIDS is not just a health issue, but a development issue (World Bank 1997).
An irnportant caveat is that both the health sector perspective and the societal perspective
would allocate  vaccine  based on ability  to pay just like any other commodity. Rationing by ability toD
pay, based on the societal  perspective model would still deny AIDS vaccine  to roughly 700 million
LDC infants who would have obtained earlier  protection had they been born in wealthier countries.
Unless world leaders agree  to policies supporting public and private cooperation to correct inequiry,
the AIDS vaccine is likely  to be allocated  as unequally  as any other scarce  commodity.
Is There  Enough  AIDS Vaccine  Research  & Development?
The AIDS vaccine allocation that we project is compatible with substanial profitability
depending on the marginal  cost of the vaccine. Profits in the pharmaceutical  industry are difficult to
predict because regulators retain tight control over firms' abilities  to use the monopoly privileges  they
have earned through research. Although potential demand is important in projecting  profit, potential
regulations  are equally  important. It is unlikely  that any pharmaceutical  company could afford to
behave like an unfettered monopolist in setting profit margins for the AIDS vaccine, but unless the
vaccine  production costs are exorbitant, a markup of $1.00  per course of vaccine would generate
between $1-4 billion in profit. One route to higher profits is the ability to charge wealthier countries
more than poorer countries for pharmaceuticals. Regulatory  changes discussed by the EEC (Danzon
1997),  and statements by US Congressmen (Russell  1997)  threaten to erode this option. The recent
experience  of South Africa indicates that when poorer countries can obtain life-saving  AIDS drugs at
14lower prices, the temaptation  to re-import them proves irresistible to politicians.  Credible signals  that
international  regulatory  institutions were prepared to tolerate and enforce higher profit margins for a
pharmaceutical  firm.  with a patent on the AIDS vaccine  would substantiaLLy  inflate the estimates of
future profitability  and stimulate  private investment in A]DS vaccine research.
Conclusion
Th.is  paper has offered depictions of two models of AIDS vaccine allocation based on ability
to pay and one alternative model of alLocation  based on equity. The ability  topay  modelwas  based on
predictors of vaccine uptake such as incidence,  medical  spending, and GDP/capita  that were proven
empirically  to have been associated  with regional uptake of Hepatitis B vaccine and Hemophilus
Influenza 13  vaccine (Miller  and Flanders 1999). The equiy  modelwas  based on what demand would
be if populations with higher the HIV/AIDS risk had the financial  resources of Western Europeans.
The model reveals that large disparities  in the attention given to HIV/AIDS  could be based on
global  resource inequalities. The relatively  low risk of a Western  European man makes reducing this
HIV/AIDS risk a $789 concern, but if that same  man were transplanted to sub-Saharan  Africa
HIV/AIDS would be a $48,577  crisis.
Our f6iadinig  that financing  the AIDS vaccine sclely  within the fixed budget of a ministry of
health could exclude large and vulnerable  populations fzom  vaccine receipt offers a strong reminder
that HIW/AIDS must be considered a development issue affecting an entire economy.
Nevertheless  we find that allocation of AIDS vaccine  b:tsed on societal  ability to pay would still
exclude large numbers of poor infants who would be inmunized if they were born in more
developed regions. Policymakers  concerned with equityr  in health need to redouble efforts to make
financing  the human confrontation with AIDS a global, rather than a regional,  issue.
15References
Anderson, R. M., and CG.  P. Garnett. 1996.  "Low-efficacy  HIV vaccines:  potential for community-based
intervention  pIogrammes  ". Lancet 348:1010-3.
Barnhart, H. X..,  M. B. Caldwell,  P. Thomas, L. Mascola,  I. C'rtiz,  H. W. Hsu, J. Schulte,  R. Parrott, Y.
Maldonado, and R. Byers. 1996.  "Natural history of human immunodeficiency  virus disease  in
perinatally  infected children:  an analysis  from the Pediatric Spectrum of Disease Project." Pediatrics
97:710-6.
Bartlett,  John. 1998.  Medical  Management  of  HI VInfection.  Baltmore: Port City Press.
Bernard, RP, U Zellweger,  J Wang, and B Somaini. 1998. "WXorld  Status & Prospects of Recent Dynamics  of
Adult HIV Spread." in 12th  World  AIDS  Conference  Geneva.  Geneva.
Biggar,  R. J., and P. S. ]Rosenberg.  1993.  "HIV infection/AIDS in the United States during the 1990s." Clin
Infect  Dis 17 Suppl 1:S219-23.
Brooks, A, FT Cutts,  J Justice, and G Walt. 1999.  "Policy Study  of Factors Influencing the Adoption of New
and Underutilized  Vaccines in Developing Countries.". San Francisco and London: University  of
Califcrnia at San  Francisco
London School of Hygiene.
Brown, Tim, and Werasit Sittitrai.  1995. "The Impact of HIV in Children in Thailand." .Bangkok:  Thai
Red Cross Society.
China Ministry  of Health, and UN Theme Group on HIV/AIDS in China. 1997. "China Responds to AIDS:
HIV/AIDS Situation  & Needs Assessment  Report." : China Ministry  of Health.
Crofts, N., G. Reid, and P. Deany. 1998.  "Injecting drug use and HIV infection in Asia. The Asian Harm
Reduction Network ." Aids 12:S69-78.
Curran,  J. W., H. NV.  J  affe, A. M. Hardy, W. M. Morgan,  R. M. Selik,  and T. J. Dondero. 1988.  "Epidemiology
of H]:V  infection and AIDS in the United States."  dcience  239:610-6.
Cutts, Felicity  T., Walter A. Orenstein, and Roger H. Bernier. 1992.  "Causes of Low Preschool Immunization
Coverage  in the United States."  Annual  Review  ofPublic  Health  13:385-398.
Danzon, P. 1997.  Pharmaceutical  Price  Regulation:  National  Poli ies  vs.  Global  Interests.  Washington, DC: AEI Press.
Datta, P., J.  E. Embree, J. K. Kreiss, J.  0. Ndinya-Achola,  Mq.  Braddick,  M. Temmerman, N. J. Nagelkerke,
G. M:aitha.,  K  K. Holmes, P. Piot, and et al. 1994. 'Mother-to-child transmission of human
immunodeficiency  virus type 1: report from the Nairobi Study ."  J Infect  Dis 170:1134-40.
Dupuy,  J.M., and L. Freidel. 1990. "Lag Between  Discovery and Production of New Vaccines for the
Developing World." Lancet  336:733-34.
Gold, Marthe R, Joanna Siegel,  Louise Russell,  B, and Milton C. Weinstein. 1996.  Cost-effectiveness  in Health  and
Medisine.  New  York: Oxford University Press.
Gray, R. H., IM.  J. Wawer, D. Serwadda,  N. Sewankambo,  C. Li, F. Wabwire-Mangen,  L. Paxton, N.
Kiwanuka,  G. Kigozi,J. Konde-Lule,  T. C. Quinn, C. A. Gaydos, and D. McNairn. 1998.
"Population-based study of fertility  in women with HIV-1 infection in Uganda." Lancet  351:98-103.
Guerena-Buwgueno,  F., A. S. Benenson, andJ. Sepulveda-Amor.  1991. "HIV-1 prevalence in selected Tijuana
sub-populations."  Am J Public  Health  81:623-5.
17Hall, A.  J., R. L. Roberston, P. E. Crivelli,  Y. Lowe, H. Inskip, S. K  Snow, and H. Whittle. 1993. "Cost-
effectiveness  of hepatitis B vaccine  in The Gambia." Trans  R Soc  Trop  Med  Hyg 87:333-6.
Hanenberg, R., and W. Rojanapithayakom.  1998. "Changes in prostitution and the AIDS epidemic  in
Thailand." AIDS  Care  10:69-79.
Health Care Financing Administration. 1998. "Public Use Data National Physician  Fee Schedule  Payment
Amount File.".
Isomura, S., and M. Mizogami.  1992.  "The low rate of HIV infection in Japanese homosexual and bisexual
men: an analysis  of HIV seroprevalence  and behavioural  risk factors." Aids 6:501-3.
Kim-Farley,  R., and EPI Team. 1992. "Global Immunization." Annual Reviews  ofPublic  Health  13:223-37.
MacDonald,  M., A. D. Wodak, R. Al, N. Crofts, P. H. Cunningham, K. A. Dolan, M. Kelaher, W. M. Loxley,
I. van Beek, and J. M. Kaldor. 1997. "HIV prevalence  and risk behaviour in needle exchange
attenders: a national study. The Collaboration  of Australian  Needle Exchanges." MedJAust  166:237-
40.
MacKellar,  D., L. Valleroy,J. Karon, G. Lemp, and R. Janssen. 1996.  "The Young Men's Survey:  methods for
estimating  HIV seroprevalence  and risk factors among young men who have sex with men." Public
Health  Rp 111:138-44.
Mann,  Jonathan, Daniel Tarantola, and Thomas W. Netter (Eds.). 1992.  AIDS  in the World.  Cambridge,  MA:
Harvard University.
Mastro,  T. D., D. Kitayaporn, B. G. Weniger, S. Vanichseni,  V. Laosunthorn, T. Uneklabh, C. Uneklabh, K.
Choopanya,  and K. Limpakarnjanarat.  1994.  "Estimating the number of HIV-infected injection drug
users in Bangkok: a capture--recapture  method ." Am J Public  Health  84:1094-9.
McCarthy,  M. C., F. S. Wignall,  J. Sanchez, E. Gotuzzo, J. Alarcon, I. Phillips, D. M. Watts, and K. C Hyams.
1996. "The epidemiology  of HIV-1 infection in Peru, 1986-1990."  Aids 10:1141-5.
Miller,  Mark, and D Flanders. 1999.  "A model to estimate  the probability of Hepatitisb- and Haemopbilus
influenzae type b- vaccine uptake into national vaccination  programs." Vaccine  Forthcoming.
Morgan,  D., G. H. Maude, S. S. Malamba, M.  J. Okongo, H. U. Wagner,  D. W. Mulder, and J. A. Whitworth.
1997.  "HIV-1 disease progression and AIDS-defining  disorders in rural Uganda." Lancet  350:245-50.
Nichter, Mark. 1995. "Vaccinations  in the Third World: A Consideration of Community Demand." Social
Science  and  Medicine  41:617-632.
O'Connor, C. C., G. Berry,  R. Rohrsheim, and B. Donovan. 1996. "Sexual  health and use of condoms among
local and international sex workers in Sydney." Genitourin  Med 72:47-51.
Over, Mead, Randall  P. Ellis,Joyce H. Huber, and Orville Solon. 192. "The Consequences of Adult Ill
Health." Pp. 161-199  in The  Health  ofAdults  in the  Developing  World,  edited by Richard G. A.  Feachem,
Tord Kjellstrom, Christopher J.L. Murray,  Mead Over, and Margaret Phillips. Washington, DC:
World Bank.
Phoolcharoen, Wiput, Viroj Tangcharoensathien,  Siriwan  Pitayarangsarit,  Sukhontha Khongsin, Vijj
Kasemsup, and Sripen Tantivess. 1999. "The Potential Demand for an AIDS Vaccine in Thailand." .
Nonthaburi, Thailand: Health Systems  Research Institute.
Reddy,  Marlita (Ed.). 1994.  StatisticalAbstract  of  the World.  Detroit, MI: Gale Research Inc.
Russell,  Philip K. 1997. "Economic Obstacles to the Optimal Utilization of an AIDS Vaccine."  Journal  of  the
InternationalAssociation  of  Physicians  in  AIDS  Care  September.
Sy, F. S.,  C. L. Chng, S. T. Choi, and F. Y. Wong. 1998.  "Epidemiology of HIV and AIDS among Asian and
Pacific  Islander Americans."  AIDS  Educ  Prev  10:4-18.
UNAIDS, and WHO. 1998a.  Report  on  the  global  HIV/IAIDS  epidemic  -June 1998.
18UNAIDS, and WHO. 1998b. UNATDS/ WIO  HI V/AIDS  epidemic  update  -December  1998.
United Nations. 1  997. Demographic  Yearbook  1995.  New York: United Nations.
World Bank. 1997. Confronting  AIDS: Public  Priorities  in a Global'Epidemic.  Washington, DC: Oxford University
Press.
World Bank. 1998. World  Development  Report,  1998.  New York: Oxford University  Press.
19Table  1.  Tar et  Groups  and  Rationale.  See  Appendix  for Population  Size  Estimates.
Groups  Analyzed  Rationale  Data  Sources  for
Estimating  Population
1. Infants/Toddlers  Can add AIDS vaccine to standard  (United Nations  1997)
Aged 0-4  battery of Expanded  Program  on
Immunization  (EPI) vaccines.
Can enfotce  receipt with school  entry
requirements
2. Children/Teens  Transition  period  from low risk to high  (United Nations  1997)
Aged 5-14  risk
Many Accessible through  schools
3. Women,  High  risk group  (United Nations  1997)
aged  15-49  Often  accessible  through  antenatal  care
4. Men,  High risk group  (United Nations  1997)
aged 15-49
5.  Not  targeted
Older Adults  Generally lower risk
IGenerally  lower  contagion  to  others
Other  Target  Grou  s
Medical Personnel  Highly accessible through  medical system  (Reddy 1994)
Highly  motivated  to  obtain  vaccine
Men Who Have  Sex With  High risk group  (Biggar and Rosenberg  1993; China
Men  High rate of contagion  Ministry of Health  and  China 1997;
Accessible via NGOs  in developed  Isomura  and  Mizogami  1992;
countries  MacKellar et al. 1996; Sy et al. 1998)
Military Staff  Highly accessible through  military  (Reddy 1994)
medical facilities
Military & strategic interest  in their
immunity
IV Drug Users  High risk group  (China Ministry  of Health and  China
High rate of contagion  1997; Crofts, Reid and Deany  1998;
Guerena-Burgueno,  Benenson  and
Sepulveda-Amor  1991; MacDornald
et al. 1997; Mastro  et al. 1994;
McCarthy  et al. 1996)
Commercial  Sex Workers  Highest  risk group  in many areas  (Brown and Sittitrai 1995; China
High rate of contagion  Ministry  of Health  and  China  1997;
Hanenberg  and Rojanapithayaakom
1998;  O'Connor  et al. 1996)
20Table  2: Present value lost per new case of AIDS by age and by region.  [1]
Region  Infants/Toddlers  School Children  Average for Adults
(age  0-4)  (age  5-14)  (age  15-49)
Western Europe, Medical  $255,014  $255,014  $255,014
Western  Erope.  Societal  III  $573,552  $683,102  $583,263
North Africa & Middle  East, Medical  $1,335  $1,335  $1,335
I North Africa & Middle East,  Societal  $103,300  $1 38,368  1  $11 7,55  9
SbD-Saharan  Ariica,  Medic&-UL  $38  $38  $38
Sub-Saharan  Africa, Societal  $16,140  $21,678  $18,386
South & South-East Asia, Medical  $441  $441  $441
South & South-East Asia, Societal  $53,829  $72,190  $61,277
Eastern Europe & Central Asia, Medical  $5,035  $5,035  $5,035
Eastern Europe & Central  Asia, Societal  $31,274  $40,298  $34,934
China, Medical  $1,896  $1,896  $1,896
China, Societal  $10,972  $14,093  $12,238
Japan,  Medical  $150,591  $150,591  $150,591
Japan, Societal  $801,166  $1,024,909  $821,001
Korea,  Medical  $67,031  $67,031  $67,031
Korea, Societal  $218,860  $271,077  $223,489
Ramt  Asin & Pacific- Medical  $2,820  $2,820  $2,820
East  Asia  & Pacific,  Societal  $25,151  $32,831  $28,266
Australia & New  Zealand, Medical  $122,163  $122,163  $122,163
Australia  & New Zealand,  Societal  $409,977  $508,961  $418,752
North  America, Medical  $299,894  $299,894  $299,894
North  America,  Societal  $650,616  $771,235  $661,309
Caribbean,  Medical  $3,322  $3,322  $3,322
Caribbean,  Societal  $68,946  $91,515  $78,101
Latin America, Medical  $1,942  $1,942  $1,942
Latin  Amnerica, Societal  $42,683  $56,694  $48,366
[11 Discounting  at 3%/.  Note  that this  places less weight  on the productivity  losses of children  who  acquire  AIDS.
[2] "Societal"  refers to the sum of medical and productivity  lossesTable  3: Health  Sector Perspective  Estimates.  Net  Expected  Benefit  of Vaccination  by Group  and By Region.  Numbers  in parentheses  are the values
that  would  be obtained  if the ability to pay in that  region  were equal  to that  of Western  Europe  Negative  values  indicate  that  the savings  to the
medical  sector  from  vaccination  do not  exceed  vaccine  delivery  costs.
More  Developed  Countres  Infants/Toddlers  Childrenrreens  Women  Men  Female CSW  MSM  IDUs
(age  0-4)  (age 5-14)  (age 15-49)  (age 15-49)
Western Europe (WE)  $31.61  $105.39  $87.13  $342.87  $4,945.84  $14,784.09  $12,625.79
($31.61)  ($105.39)  ($87.13)  ($342.87)  ($4945.84)  ($14784.09)  ($12635.79)
Australia & NZ (A & NZ)  -$2.10  $16.02  $0.51  $72.00  $176.21  $8,682.82  $652.14
($0.19)  ($38.02)  ($5.64)  ($154.87)  ($372.40)  ($18129.78)  ($1365.91)
North America (N. Am)  $87.94  $262.94  $209.51  $850.66  $61.61  $10,899.69  $12,471.42
($74.15)  ($222.96)  ($177.52)  ($722.73)  ($51.76)  ($9267.86)  ($10604.38)
Japan  -$3.74  $95.23  $0.83  $77.66  $1,071.98  NA  NA
-($3.77)  ($163.82)  ($3.97)  ($133.07)  ($1817.88)  NA  NA
S. Korea  -$3.72  $44.46  $1.19  $31.05  $474.94  NA  $15,898.62
-($3.14)  ($179.16)  ($15.54)  ($129.13)  ($1817.88)  NA  ($60495.45)
Less Developed  Countmes
North  Africa & Middle  East (NA  & MC)  -$0.41  -$0.06  -$0.15  $0.89  $0.85  NA  $12.44
($17.04)  ($82.63)  ($66.01)  ($265.53)  ($257.17)  NA  ($4380.80)
Sub-Saharan  Africa (SSA)  -$0.10  $1.07  $2.61  $2.67  $15.83  NA  -$10.50
($2,656.19)  ($10,513.90)  ($20,818.01)  ($21238.58)  ($109414.76)  NA  NA
South  & South East Asia (SSEA)  -$0.30  $1.23  $1.32  $4.59  $98.17  NA  $240.50
($112.70)  ($999.10)  ($1,051.71)  ($2945.69)  ($57110.57)  NA  ($145285.01)
East Europe  & Central  Asia (EE  & CA)  -$0.22  $9.74  $8.14  $31.80  $1,187.34  NA  $524.60
$13.66  $518.01  $437.36  ($1635.70)  ($60163.24)  NA  ($26595.52)
East Asia & Pacific  (EA  & Pac)  -$0.45  $0.11  $0.46  $6.12  $19.65  $382.46  $668.40
(excluding  China,  Japan,  S. Korea)  ($4.19)  ($54.46)  ($86.02)  ($598.58)  ($51919.56)  NA  ($52952.65)
China  -$0.46  $0.78  $0.17  $4.44  $13.04  NA  $449.20
($4.40  $171.90  $90.04  ($63.44)  ($5638.66  ($1352.82)  ($4194.79)
Caribbean  $5.12  $27.91  $36.63  $76.03  $675.81  NA  $689.27
($430.80)  ($2,180.90)  ($2,849.86)  ($5874.73)  ($51919.56)  NA  ($52952.65)
Latin  America  (L Am)  $0.05  $4.05  $2.86  $14.35  $61.92  $317.41  $375.68
($71.09)  ($597.18)  ($440.87)  ($1948.86)  ($8196.25)  ($41744.06)  ($49395.82)Table  4: Societal  Perspective  Estimates.  Net  Expected  Benefit  of Vaccination  by Group  and By Region.Numbers  in parentheses  are the values  that  would  be obtained  if
the ability to  pay  in that  region were  equal to that  of Western  Europe.  Negative  values  indicate  that  the  savings to the GDP  from  vaccination  do not  exceed  vaccine  delivery
costs.
More Developed  Countries  Infants/roddlers  Childrenlreens  Women  Men  Female  CSW  MSM  IDUs
(age 0-4)  (age  5-14)  (age  15-49)  (age  15-49)
lWestern  Europe (WE)  $76.34  $289.38  $204.69  $789.62  $11,330.35  $33,819.38  $28,895.81
($76.34)  ($289.38)  ($204.69)  ($789.62)  ($11330.35)  ($33819.38)  ($28905.81)
Australia  & New Zealand (A & NZ)  $2.87  $80.08  $11.97  $257.01  43 91  $2Q  77320  $2,245.641
($5.69)  ($108.92)  ($18.33)  ($359.63)  ($857.18)  ($41471.60)  ($3129.52)
North America (N Am)  $195.71  $682.81  $467.07  $1,880.91  $140.92  $24,040.42  $27,506.31
($172.03)  ($604.30)  . ($411.45)  ($1658.43)  ($123.80)  ($21202.75)  ($24259.60)
Japan  -$2.61  $671.32  $22.35  $441.18  $5,862.10  NA  NA
-($3.21)  ($445.89)  ($14.51)  ($311.06)  ($4163.25)  NA  NA
S. Korea  -$3.08  $0.00  $13.31  $112.85  $1,592.85  NA  $53,016.81
-($1.80)  ($488.67)  ($40.97)  ($300.76)  ($4163.25)  NA  ($138369.76)
Less  Developed  Countries
North  Africa & Middle  East (NA & MC)  $6.61  $44.61  $30.15  $122.10  $118.25  NA  $2,008.66
($38.95)  ($222.19)  ($151.61)  ($607.96)  ($588.84)  NA  ($10020.35)
Sub-Saharan  Africa (SSA)  $167.64  $893.29  $1,500.50  $1,530.82  $7,888.27  NA  -$10.50
($5,974.66)  ($28,164.31)  ($47,615.30)  ($48577.24)  ($250252.55)  NA  NA
South  & South East Asia (SSEA)  $23.40  $232.47  $252.33  R7n7  43  13 722SX  NA  $34.899.80
($254.11)  ($2,677.11)  ($2406.10)  ($6737.97)  ($130623.14)  NA  ($332294.47)
East Europe  & Central  Asia (EE  &  $1.24  $81.44  $59.48  $223.64  $8,241.34  NA  $3,642.89
CA)
($31.34)  ($1,388.44)  ($1,000.96)  ($3741.80)  ($137605.15)  NA  ($60829.55)
East Asia & Pacific (EA & Pac)  -$0.04  $6.58  $9.09  $65.90  $201.46  $3,838.83  $6,705.43
(excluding  China,  Japan, S. Korea)  ($10.04)  ($146.73)  ($197.38)  ($1369.71)  ($118750.33)  NA  ($121113.20)
China  -$0.29  $9.03  $3.84  $31.36  $86.94  NA  $2,902.80
($10.53)  ($461.32)  ($206.57)  ($1518.05)  ($12897.31)  ($3094.79)  ($9594.91)
Caribbean  $116.11  $782.33  $872.46  $1,798.86  $15,900.65  NA  $16,217.05
(  $969.54)  ($5842.79)  ($6,518.80)  ($13437.25)  ($118750.33)  NA  ($121113.20)
Latin America (L Am)  $11.48  $132.38  $83.21  $369.22  $1,554.12  $7,916.88  $9,368.13
($160.52)  $1,600.51)  ($1,008.99)  $4458.06)  ($18746.99)  ($95477.07)  $112978.07)Figure 1. Health Sector Perspective Algorithm for AIDS Vaccine Distribution.  Callout boxes are not
comprehensive but suggest the principle populations receiving  vaccine as a function of price. Details and region
abbreviations listed in Table 3 Dotted lines show sensitivity  of demand estimates to variation in HIV incidence
rates.
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24Figure  2. Societal  Perspective  Allocation  Algorithm  for AIDS  Vaccine  Distribution  Callout  boxes  are not
comprehensive  but suggest the principle  populations  receiving  vaccine  as a function  of price.  Details  and
abbreviations  listed in Table  4.  Dotted  lines show  sensitivity of demand  estimates  to variation  in HIV incidence
rates.
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27Appendix  A: Estimating  AIDS Incidence  over 10 Years  by Population  Subgroup
We base our incidence rates on UNAIDS estimates for regional populations of the world (Bernard et al.
1998; UNAIDS and WHO 1998b). It is important to point out that the most common  identifiable risk factor
for HIV/AIDS  in most parts of the world is being a heterosexual adult who has had sex with multiple partners
or with a partner with multiple partners.  In those few areas  where the bulk of incident HIV cases have some
other identifiable  risk factor,  attributing UNAIDS incidence estimates to the general population results in an
overestimate of  risk. Sensitivity  analyses  show that demand at higher vaccine prices is more sensitive than at
prices under $10.00. As improved HIV incidence data are assembled our model will be updated.
Using UNAIDS estimates of incidence rates for adults in the major regions of the world, (Bernard et al.
1998;  UNAIDS and WHO 1998b) we make the assumption that the gender ratio of prevalent cases is a good
approximation of the gender ratio of incident cases. This.  assumption is an oversimplification of the complex
dynamics of the AIDS epidemic, but it permits us to leverage what we know about prevalence among target
groups at the regional level to offer a rough suggestion of annual attack rates in the adult target groups.
Sensitivity  analyses discussed in the text reveal how important these assumptions are in determining the results of
the model.
We assume that annual attack rate in the cohort of age 5-14 is 50% of adult incidence because over the
subsequent decade, half of the life years of this cohort will be spent in the age group  15-24.
We assume that incidence for a cohort age 0-4 is exclusively  due to mother-child transmission. We use
as the probability that the child of a seropositive mother will experience HIV seroconversion prior to age 10 the
estimate of 42.8% and the probability that the infection occurred post-natally of 440/o  (Datta et al. 1994). When
we estimate decadal  incidence in this group as 42.8% x 44%X  HIV Prevalence in Women Age 15-49,  we are
assuming that births are as frequent for HIV+  as HIV- women although this may not be the case (Gray et al.
1998). Our sensitivity  tests cover incidence rates in this cohort that are as much as 25% lower to cover this
possibility.
To convert annual attack rates, Ait,  to decadal  incidence, Ijlo  we use the formula:
10
Ijo  =  (I-  I jt  )A,(1  + r)'
t=l
28where r is the discount rate. We adopt the approximation that 1-]:jii =l. Discounting is necessary because
seroconversion t years into the ten year period postpones the costs by t additional years.
Appendix Table Al shows the source data on attack rates and our estimates of the discounted decadal
incidence rates for each group.
Appendix Table Al.: Decacal  Incidence  Rates for General  lopulation by Regional Group
Region'  Adult Incidence  InfantrToddlers  Children/reens  Women  Men
(Betnard  et al.  1998;  (age  11-4)  (age 5-14)  (age  15-49)  (age  15-49)
UNAIDS  and WHO
1998b)
HIV Conversions  per  HIV Conversions  per 100,000  Person-DECADES
100,000  Person-yrs
WadernEurope  14.56  18.73  57.31  47.75  181.47
NoflhAfrica&MiddleEast  10.35  9.17  43.47  34.77  139.09
Sub-SaharanAfrica  1277.76  . 1,389.04  5,497.43  10,884.91  11,104.81
South&  South-EastAsia  127.08  59.19  522.64  550.15  1,540.41
Etern  Europe&CentralAsla  48.41  7.40  271.10  228.93  855.48
China  2.56  90.14  47.34  313.23
Japan  0.23  87.85  4.28  347.14
Korea  0.56  20.66  10.33  72.30
EastAu"a8Pacific  21.85  2.45  28.74  45.23  69.71
Ausria & NowZealand  5.16  2.30  22.08  5.15  83.17
North  Amdeca  27.87  40.97  118.77  95.02  380.08
Canbean  268.31  225.51  1,140.54  1,490.30  3,071.85
Laln  Amerca  72.90  37.43  312.50  230.77  1,019.22
Estimates cf incidence in CSWs, IDUs and MSM are more problematic.  Clearly the incidence rates in
these populations have been higher than those of the general adult population as reflected in their higher
prevalence rates. Assuming that incidence rates and case fatality rates in both the high risk groups and general
29population have always  both been subject to the exact same historic trends permits the following approximation:
PR=(Prevalencei /Prevalence)  -IR=(Incidencei/Incidence)  .
Where subscripts ii and j denote two different risk groups.
Although it is doubtful that this assumption holds it does offer us a means of estimating incidence in
CSWs,  IDUs, and MSM which we can then subject to rigorous sensitivity  analysis. Our procedure is to multiply
the adult population incidence estimates listed in the table above by the ratio of prevalence in the high risk
prevalence in adult population.  These incidence figures are tabulated below. We did not compute incidence for
the high risk groups for regions where there was no reason to believe that the regional governments would be
able to effectively  target the high risk group. In each of these cases the high risk groups are subsumed within the
general population. Fortunately for our estimates the population sizes in these groups are small and do no L
contribute heavily to the overall number of doses of vaccine that are allocated by the algorithm.
Appendix Table A2: Decadal Incidence  Rates for High  Risk
Population  by Regional Group
Region  CSWs  [  MSM  IDUs
Westem  Europe  0.025933523  0.077320318  0.066087963
North  Atrica  & Middle  East  0.001347224  NA  0.022907548
sub-Saharan  Africa  0.572075489  NA  NA
South  & South-East  Asia  0.298604078  NA  0.759622341
Eastern  Europe  & Central  0.314564878  NA  0.139056759
Asia
China  0.009526755  NA  0.316321247
Japan  0.009526755  NA  NA
Korea  0.009526755  NA  0.316321247
East  Asia  &  Pacific  0.009526755  0.181102604  0.316321247
Australia  & New  Zealand  0.001969122  0.094813205  0.007163664
North  America  0.029262008  0.048478849  0.055466791
Carribean  0.271462984  NA  0.276864461
Latn  America  0.042856538  0.218260594  0.258267671
30Appendix  B: Estimating  The Medical  Costs  of AIDS by Region
Because exising estimates of worldwide health care costE for AIDS assume that each AIDS patient
consumes tie full complement of medical treatments that are statidard in that region, they provide an admitted
overestimate (Mann,  Tarantola  and  Netter  1992).  We adjust these estimates downward by replacing
the assumption of fiffl  complement utilization by a health care access index. For each region of the world, we
compute the access index as the ratio of physicans per capita in region j to the physician per capita ratio in
Western Europe. Appendix Table B shows our revised AIDS health care costs for each person-year of AIDS.
We inflate the Mann et  il. (1992)  cost estimates to 1997 dollars using the United States Consumer Price Index
for medical care. We are aware that new treatments available,  primarily in developed countries, have substantially
increased the medical costs in these regions since 1992 and plan to update Table B as estimates of these new
treatment costs are produjced.
Appendix Table B: Ad'justed  Medical Costs per Person Year of AIDS by Region
Region  Health  Cost/Person  CostVPerson  Year  of  Access  Adjusted
Access  Year of AIDS,  AIDS  $1997  $US  [3]  Medical
Index [11  1990  Cost/Person Year
of AIDS in $ 1997
Western Europe  1.00  $22,391  $31,716  $31,716
North Africa & Middle East  0.23  $2,446  $3,465  $809
Sub-Saharari  Africa  0.04  $393  $557  $23
South & South-East Asia  0.11  $1,700  $2,408  $267
Eastern Europe, Ctrl. Asia[4]  1.42  $1,520  $2,153  $3,050
East Asia & Pacific excl  0.71  $1,700  $2,408  $1,708
China, Japan, &';. Korea [2]
China  [2]  0.48  $1,700  $2,408  $1,148
Japan  0.57  $23,160  $32,805  $18,729
Republic  of Korea  0.25  $23,160  $32,805  $8,337
Australia & New Zealand  0.77  $14,015  $19,852  $15,193
North America  0.82  $31,995  $45,320  $37,298
Caribbean  0.66  $2,157  $3,055  $2,013
Latin America  0.42  $1,992  $2,822  $1,177
[1]  Health  Access  Index  for  each  region  is Physicians  per  Capita  relative  to  P  ,ysicians  per  Capita  in  Westem  Europe
[2]  Applying  Mann  et  al (1992)  figure  for  S.  SE  Asia
[3]  Adjusted  using  US  Medical  Care  1990-98  lnflator=1.42
(4]  Central  Asia  has  a surplus  of  physicians  by  Western  European  standards.  Whether  this  translates  into  increased  medical
access  is unclear.
31Appendix  C. Number  of People  in Each Regional  Group
In Appendix Table C. Displayed are the numbers of people in each region of the world according to the
major age and sex groups considered in the model. Data are from UNAIDS, 1998 (UNAIDS and WHO 1998a)
and United Nations, 1997 (United Nations 1997).  Data on the numbers of CSWs, IDUs, and MSM in the world
are quite limited. Based on the sources listed in Table 1,  we make the following assumppdons:  CSWs  make up
0.7% of adult women (age 15-49)  in every region of the world, IDUs make up 0.10% of adult men (age 15-49)  in
every region of the world, and MSM make up 3% of adult men (age 15-49) in every region of the world.  Because
it is doubtful that MSM and IDUs will  be effectively  targeted in many regions of the less developed world we
simply set the effective population estimate for these groups to zero in the regions noted by "NA" in Appenlix
Table A2.
Sensitivity  analyses  indicate that because these high risk groups make up a relatively small proportion of
the population facing a risk of HIV/AIDS  that the amount of vaccine required is not changed significantly  even
if we set the size of these populations to zero. However regional policy makers will need to form better estimates
of these population's sizes because their high risk makes allocating vaccine to them a priority even at high
vaccine  prices.
Appendix  Table  C: Numbers  of People  In Each Risk  Category  By Region
Povulation  Cateaories
Total  Children  0-4  Children  5-14  Women 15-49  Men 15-49  Surn  of
Population  I4Included
Categories
Western  Europe  403,603,000  24,010,860  48,021,720  100,565,500  100,565,500  273,1  63,580
North  Africa  &  Middle  East  322,211,000  44,465,118  77,975,062  82,129,500  82,129,500  286,699,180
sub-Saharan  Africa  593,027,000  100,221,563  160,710,317  134,219,500  134,219,500  529,370,880
South  & South-East  Asia  1,859,821,000  228,757,983  420,319,546  477,255,000  477,255,000  1,603,567,529
Eastern  Europe  &  Central  Asia  373,424,000  29,500,496  60,121,264  96,692,500  96,692,500  283,006,760
East  Asia  & Pacific  excluding  C,  J,  & K  36,614,000  3,331,874  6,114,538  10,475,000  10,475,000  30,396,412
China  1,243,738,000  104,473,992  222,629,102  352,474,500  352,474,500  1,032,052,094
Japan  125,638,000  7,161,366  13,443,266  30,866,500  30,866,500  82,337,632
Republic  of  Korea  45,717,000  3,428,775  6,583,248  13,462,500  13,462,500  36,937,023
Australia  & New  Zealand  21,891,000  1,641,825  3,130,413  5,725,000  5,725,000  16,222,238
North  America  301,591,000  22,016,143  43,127,513  78,138,500  78,138,500  221,420,656
Carribean  30,932,000  3,185,996  6,124,536  8,184,000  8,184,000  25,678,532
Latin  America  455,247,000  48,711,429  95,146,623  120,741,000  120,741,000  385,340,052
World  5,813,454,000  620,907,420  21,163,447,148  1,510,929,000  1,510,929,000  4,806,212,568Policy  Research Working  l'aper  Series
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